The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26

Outcome Description:

Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.

Outcome Time Frame:

Week 0, Week 26

Safety Issue:

No

Principal Investigator

Anne Bloch Thomsen

Investigator Role:

Study Director

Investigator Affiliation:

Novo Nordisk

Authority:

United States: Food and Drug Administration

Study ID:

NN2211-1860

NCT ID:

NCT00700817

Start Date:

June 2008

Completion Date:

June 2010

Related Keywords:

• Diabetes
• Diabetes Mellitus, Type 2
• Diabetes Mellitus
• Diabetes Mellitus, Type 2